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Abstract
Background: Ovarian cancer is a deadly female reproductive cancer. Understanding the biological mechanisms
underlying ovarian cancer could help lead to quicker and more accurate diagnosis and more effective treatments.
Both changes in microRNA(miRNA) expression and miRNA/mRNA dysregulation have been associated with ovarian
cancer. With the availability of whole-genome miRNA and mRNA sequencing we now have new potentials to
study these associations. In this study, we performed a comprehensive analysis of miRNA and mRNA expression in
ovarian cancer using an integrative network approach combined with association analysis.
Results: We developed an integrative approach to construct a network that illustrates the complex interplay among
miRNA and gene expression from a systems perspective. Our method is composed of expanding networks from
eQTL associations, building network associations in eQTL analysis, and then combine the networks into an integrated
network. This integrated network takes account of miRNA expression quantitative trait loci (eQTL) associations,
miRNAs and their targets, protein-protein interactions, co-expressions among miRNAs and genes respectively.
Applied to the ovarian cancer data set from The Cancer Genome Atlas (TCGA), we created an integrated network
with 167 nodes containing 108 miRNA-target interactions and 145 from protein-protein interactions, starting from 44
initial eQTLs. This integrated network encompassed 26 genes and 14 miRNAs associated with cancer. In particular, 11
genes and 12 miRNAs in the integrated network are associated with ovarian cancer.
Conclusion: We demonstrated an integrated network approach that integrates multiple data sources at a systems
level. We applied this approach to the TCGA ovarian cancer dataset, and constructed a network that provided a
more inclusive view of miRNA and gene expression in ovarian cancer. This network included four separate types of
interactions among miRNAs and genes. Simply analyzing each interaction component in isolation, such as the
eQTL associations, the miRNA-target interactions or the protein-protein interactions, would create a much more
limited network than the integrated one.
Background
Ovarian cancer is the deadliest reproductive cancer in
women, accounting for 5% of female cancer deaths. It is
estimated that there will be 21,980 new cases and 14,270
deaths from ovarian cancer in 2014 [1]. The overall 5 year
relative survival is less than 44%, but when diagnosed in
the earliest stages the 5 year survival is over 90%. [2].
Therefore, a better understanding of the biological
mechanisms of ovarian cancer is crucial to create earlier
diagnosis and more effective treatment.
MicroRNAs (miRNAs) are small (~22 nucleotides) non-
coding RNAs that regulate gene expression by targeting
complementary mRNA, which triggers a translational
blockade or degradation [3]. miRNAs have been increas-
ingly recognized as an important participant of gene regu-
lation activity [4] that affect various cellular processes [5]
and contribute to disease pathogenesis in a wide variety of
diseases [6] including cancer [7]. Changes in miRNA
expression and miRNA dysregulation have been found in
cancer, including ovarian cancer [8-13]. In another recent
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study, miRNAs were described as regulators of tumor phe-
notype [14]. Early studies show that miRNA expression
profiles can be used to classify cancer phenotypes [15]. A
study by The Cancer Genome Atlas (TCGA) found three
miRNA subtypes in high grade serous ovarian cancer [16].
By exploiting the miRNA expression profiles and their
effects on gene expression and other phenotypes in cancer,
more profound markers for prognosis can be identified
and utilized.
Genetic variation has also been determined to have
functional effects on cancer through miRNA expression as
well. Various studies have indicated the genetic variants
such as single nucleotide polymorphisms (SNPs) are asso-
ciated with cancer risk in individuals [17]. Particularly,
eQTL analysis [18-25] provides a powerful tool to study
how genetic variation affects quantitative traits, including
measurable phenotypes like gene or miRNA expression.
For instance, miRNA eQTL analysis [6,26,27] has also
been performed to find genetic loci that introduce differ-
ences in miRNA expression.
In general, eQTL analysis analyzes the effect of genetic
variation on gene expression by utilizing correlation or
regression analysis between the genotypes of a genetic var-
iant and a particular trait [25]. Such analysis assumes that
genetic variants are independent, and that the expressions
of different genes are independent as well. Nonetheless,
many genetic variants are correlated, and the genes can be
co-regulated as well. To address the correlation or interac-
tions among these genetic variants or genes, new machine
learning methods such as multi-task learning methods
[28,29] have been designed to consider all the genes dur-
ing regression while considering the network structure
among genetic variants and genes [30-32]. New methods
have also been developed to seek for other relationships,
such as redundancy among eQTLs [33] where multiple
genetic variants have the same effect on a particular trait
and are thus exchangeable.
However, it is still unclear to what extent that changes
in miRNA expression, an epigenetic marker, affect gene
expression and bring about fluctuations in biological
pathways and networks in ovarian cancer. It has recently
been determined that some miRNAs promote epithelial-
to-mesenchymal transition (EMT) and in turn, EMT
transition promotes cell mobility and invasion of cancer-
ous cells [14]. In efforts to understand such complex
effects of miRNA expression on gene expression, we
develop an integrated network approach that combines
expression quantitative trait locus (eQTL) analysis with
network analysis using various types of relationships and
interactions among miRNAs and genes.
In order to understand the effects discussed above, we
perform a genome wide eQTL analysis between miRNA
expression and gene expression in ovarian cancer. The
suggested method can help identify a set of miRNA
eQTLs that have significant impact on gene expression.
Using these miRNA eQTLs and their perturbed genes
as seed nodes for network expansion, we created an
integrated network that utilizes multiple types of net-
works such as miRNA targets and protein-protein inter-
actions. In parallel, we used another graph guided
machine learning model for eQTL analysis that incorpo-
rates correlations among miRNAs and genes simulta-
neously [30]. With these various types of relationships
combined, we are able to generate an integrated net-
work that not only captures different types of interac-
tions among these miRNAs and genes, but also includes
important cancer genes embedded in a network view.
Such an integrative approach thus generates insightful
results that could shed light on the interaction of
miRNA, gene expression and their contribution to the
development and progression of ovarian cancer.
Methods
We developed an integrative approach that combines the
strength of eQTL analysis with network analysis, toward
the goal of building an integrated network to understand
the relationship between miRNA expression and gene
expression. The integrated network is composed of various
types of relationships among miRNAs and genes, includ-
ing miRNA-gene eQTL associations, miRNAs and their
targets, protein-protein interactions, and correlation net-
works of both miRNA and gene expression.
The overall workflow of our integrative approach is illu-
strated in Figure 1. Our approach consisted of five phases,
including data preprocessing, eQTL analysis, network
association, network expansion and network integration.
Prior to analysis, we performed data pre-processing in
which, we collected and normalized the data. The next
phase of our workflow was the eQTL analysis between
miRNA and gene expression. Here, we used Matrix eQTL
to perform the analysis. In the network expansion phase,
we used TarBase [34] to identify targets based on the
eQTLs generated from Matrix eQTL [35]. Next, we found
protein-protein interactions connected with the identified
miRNA targets. In order to select the most confident
interactions, we chose the interactions with a p-value ≤
0.05. From there, we expanded the network using the
selected protein-protein interactions using DAPPLE [36],
generating the initial integrated network. Simultaneously,
in the network association phase we used MtLasso2G [30]
to discover network associations between miRNAs to
build miRNA correlation networks. Finally, we merged the
eQTL expanded network and the miRNA correlation net-
works to create the integrated network.
Data preprocessing
We downloaded miRNA isoform and mRNA expression
data for 480 samples of serous ovarian cancer from the
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Figure 1 The overall workflow of our integrative approach. The workflow to create the integrated network consisted of four phases; eQTL
analysis, network association, network expansion and network integration. We began with data pre-processing in which we collected data and
normalized it. The first phase of the workflow started with an eQTL analysis between miRNA and gene expression data using Matrix eQTL. Once
the eQTL analysis was complete, we proceeded to the network expansion phase. In the network expansion phase, we used TarBase to identify
miRNA targets based on the eQTLs found in Matrix eQTL. Next, we found protein-protein interactions for the identified targets. To select the
most confident interactions, we chose the interactions with a p-value ≤ 0.05. Then we expanded the network with the selected protein-protein
interactions using DAPPLE, creating the first integrated network. Simultaneously, we used MtLasso2G to discover network associations between
miRNAs, creating miRNA correlation networks. We then combined the eQTL expanded network with the correlation networks to create the final
integrated network.
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TCGA data portal [37]. Both data sets were generated
on the Illumina HiSeq platform. To pre-process the
data, we removed samples with missing data and
extracted quantifications for 183 miRNAs and 13,536
genes. To reduce the variation between samples, we
used between-sample quantile normalization to normal-
ize both the miRNA and gene expression data.
Network expansion
To help exploit the relationships between miRNA and gene
expression, we performed an eQTL analysis between the
miRNA expression and gene expression profiles. The eQTL
analysis was performed using Matrix eQTL, an R package
[35]. Matrix eQTL was chosen because of its efficient com-
putational time with large datasets [35] and its proven effi-
ciency in many large studies [22,23]. We performed cis
eQTL analysis, whereby we only tested miRNA and gene
pairs that were within 1 MB of each other. To test for asso-
ciations between the miRNA and genes, we used a linear
regression model provided by Matrix eQTL. To correct for
multiple comparisons, we utilized a multi-test correction
based on false discovery rate (FDR) and chose the signifi-
cant eQTLs with a FDR cutoff at < 0.01 for further analysis.
Using the eQTLs identified in Matrix eQTL as seed
nodes for an initial network, we searched for linked targets
of the miRNAs to expand the network. In order to identify
miRNA targets, we used TarBase to generate a list of the
miRNAs and their corresponding gene targets [34]. Tar-
Base is a manually curated database of all experimentally
verified miRNA targets. In generating the list, we discov-
ered that some miRNAs may have multiple designated
names associated with the 3’ untranslated region (UTR)
and the 5’ untranslated region. In this case, we used both
variations to keep it consistent with our data. For example,
if there was an ambiguous miRNA name used in the
TarBase search, it was replaced by both the -3’ and -5’ ver-
sion of the name.
We used the miRNA target genes gathered from Tar-
Base, in combination with the perturbed genes from the
eQTLs, to further extend the network using protein-
protein interactions. We chose the Disease Associated
Protein-Protein Link Evaluator (DAPPLE) [36] for this
step of network expansion since it’s been well evaluated
in finding candidate genes through expanding networks
on signals from genome wide association studies
[36,38,39]. By using DAPPLE on the miRNA target
genes and the miRNA perturbed genes in the eQTL
associations, we were able to find protein-protein inter-
actions for miRNA targets and the miRNA eQTL per-
turbed genes. To perform the link evaluation, DAPPLE
uses a statistical model to extend a network from an
input seed gene list. The protein-protein interactions
were derived from the InWeb database [40].
At each network expansion step, DAPPLE selects a
new edge from the existing node set with the highest
probability based on its significance against random per-
mutations of the protein-protein interaction network.
During the permutations, the network topology is con-
served. For our analysis, we performed 1000 random
permutations of the network. As part of our selection
criteria, we only selected the interactions that contained
a seed gene with a corrected p-value of ≤ 0.05. This
allowed us to keep those interactions with a high-confi-
dence for further analysis. We then overlapped the
selected protein-protein interactions, the eQTLs and the
miRNA-target interactions to create an initial integrated
network.
Network associations
In parallel with the network expansion, we used a two-
graph guided multitask Lasso (MtLasso2G) to perform a
second eQTL analysis [30]. MtLasso2G is an orthologous
approach capable of determining network associations.
Unlike Matrix eQTL, which we used to perform linear
regression for each pair of miRNA and gene independently
for eQTL analysis, MtLasso2G uses a sparse learning
model that incorporates the relationships among miRNAs
and genes. Here, we used a correlation expression network
among miRNAs, and another co-expressed network
among genes that potentially captured the structure of co-
regulation networks. The MtLasso2G model accomplished
eQTL analysis by adding two regularization terms based
on the two graphs on features (i.e. miRNA expression)
and labels (i.e. gene expression), which are encoded as
miRNA co-expression network and gene co-expression
network in our analysis respectively. The model can then
be learned by minimizing the following objective function
in a linear system:
min
β














|bfk − Sign(rf ,g)bgk|. (2)
The two graphs, G1 = (V1, E1) and G2 = (V2, E2)
represent the correlation networks among genes and
miRNAs respectively. V1 and V2 are the nodes in G1
and G2. E1 and E2 are the edges representing the corre-
lations among the corresponding vertices. w(·) is the
edge weight. Individual edges in G1 and G2 are repre-
sented as em,l and ef,g respectively. The correlation
between ym and yl is denoted as rm,l, and rf,g denotes the
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correlation between yf and yg. The learned b matrix
from the model represents the association between each
feature and label. Those nonzero terms stand for the
identified eQTLs. As the MtLasso2G model captures the
correlation structures among the miRNAs and genes, it
produces not only a set of eQTLs, but also network
associations. These network associations include a sub-
network capturing miRNA correlations, and another
subnetwork representing the correlations among the
perturbed genes.
Network integration
We finally created an integrated network by merging the
expanded network extended using DAPPLE, and the net-
work associations generated from the MtLasso2G model.
Specifically, we added representations of the correlation
graphs from MtLasso2G to the expanded network from
DAPPLE as following. If one miRNA was present in the
current integrated network, we added highly correlated
miRNAs. If both genes were already present in the current
integrated network, we added an edge to the network.
The edges between miRNAs and perturbed genes from
network associations in MtLasso2G are added to the
integrated network as well. By merging the networks gen-
erated from DAPPLE and MtLasso2G as stated above, we
created the final integrated network which was then
visualized using Cytoscape [41]. Integrating the networks
in this manner allowed us to conserve many of the pre-
determined relationships found early on in the analysis.
Figure 2 The integrated network incorporating multiple data sources. This network incorporated eQTLs, protein-protein interactions from
DAPPLE, and miRNA-target interactions from TarBase. miRNAs are shown in yellow nodes, and genes are shown in light blue nodes. eQTLs are
shown as green edges, protein-protein interactions are shown as blue edges, miRNA-target interactions are shown as red edges, MtLasso2G
correlation interactions are in purple, and MtLasso2G eQTLs are in gold.
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Results and discussion
Our approach generates an integrated network (Figure 2)
that incorporates the comprehensive relationship between
miRNA and gene expression. We create this network from
multiple sources of data and analysis including miRNA
eQTL and associated genes, miRNAs and their target
genes, protein-protein interactions among miRNA eQTL
perturbed genes and miRNA target genes. This network
thus captures the complexity of the interplay among miR-
NAs and genes in ovarian cancer, and point to a list of
candidate miRNAs and genes for future studies.
Our method is scalable and applicable to integrating
many genomic datasets. Here, as a demonstration of our
approach, we apply it to the miRNA and gene expression
data in ovarian cancer from TCGA [37]. After pre-
processing, we use the expression of 183 miRNAs, and
the expression of 13,536 genes from 480 samples.
We identified 44 miRNA eQTLs with a FDR < 0.01
using Matrix eQTL. There were 16 unique miRNAs,
and 44 unique genes represented in the eQTLs. We
found 310 unique target genes using TarBase, of which
244 could be used as inputs for DAPPLE. Figure 3
shows the miRNA-taget and eQTL network. There were
236 direct connections found using DAPPLE, and
145 that contained a seed gene with a corrected p-value
of <0.05. We added 9 correlated miRNAs, and 18 corre-
lated gene edges to the network based on the MtLas-
so2G correlation graph.
With MtLasso2G, we found 48 eQTLs, and were able
to add 8 of them to the network, composed of the
miRNA-target interactions found in TarBase, the eQTLs
from Matrix eQTL, and the MtLasso2G correlations.
This process created the final integrated network includ-
ing 167 nodes and 277 edges shown in Figure 2. Table 1
summarizes the number of cancer genes found in each
part of the analysis. Of the 145 gene nodes in this inte-
grated network, 26 were found to be cancer related, and
11 of those were associated with ovarian cancer [42,43],
as illustrated in Table 2.
One of the genes found in the integrated network,
AKT 1, has been implicated in tumorigenesis, specifically
in ovarian cancer [44,45]. In our analysis AT K1 was
found in the DAPPLE extended network, the miRNA-
target network and the MtLasso2G gene-correlation
graph. Figure 4 shows a subnetwork involving AKT 1 of
our integrated network. This subnetwork involves 5 miR-
NAs and 12 genes, connected by 31 edges. Three of the
edges are eQTLs, and six edges were miRNA-target
Figure 3 The miRNA-target and eQTL network. This network contains the eQTLs as well as the target genes from TarBase for the miRNAs.
The initial integrated network is formed when the protein-protein interactions for the genes in this network are added.
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interactions. Another gene in the subnetwork was ESR1,
which has been associated with breast cancer, and ESR1
expression has been suggested as a predictor of ovarian
cancer survival [46-48].
Interestingly, in addition to capturing known ovarian
cancer genes, this subnetwork provides a set of miRNAs
and genes interacting with these known cancer genes.
We propose that these interactive miRNAs and genes
offer a new list of potential miRNA and gene markers
for tumorigenesis, particularly in ovarian cancer.
Another interesting gene in the integrated network is
E2F 1 (Figure 2), which was targeted by three miRNAs.
E2F 1 has been studied as a predictor of drug resistance
in ovarian cancer, and the down regulation of E2F 1 has
been shown to inhibit growth of ovarian cancer [49,50].
Therefore, E2F 1 and their interactive partners are
worthy of follow up studies for tumorigenesis as well.
We then analyzed the role of the miRNA eQTLs in dif-
ferent diseases including cancer and particularly ovarian
cancer. Using multiple datasets (HMDD2, miRCancer,
Phenomir, miRdSNP, miR2Disease, miRPD and Marchini)
[51-57], we found that 19 of the 22 miRNAs have been
implicated in some type of disease. Of these miRNAs, 14
were associated with a form of cancer, and 12 were specifi-
cally associated with ovarian cancer. Table 3 lists these
cancer and ovarian cancer related miRNAs in our inte-
grated network. Some of these miRNAs have demon-
strated biological and clinical utility and could serve as
disease biomarkers. For example, increased expression of
hsa-miR-200c, one of the miRNAs found in our analysis,
has been associated with increased survival, decreased
chance of relapse and increased sensitivity to paclitaxel, a
chemotherapy drug [57-59]. hsa-mir-22 has been identi-
fied as an marker for both survival and recurrence of ovar-
ian cancer [60]. hsa-mir-22 has also been suggested as an
inhibitor of cell movement and invasion in ovarian cancer
[61]. Both hsa-mir-22 and hsa-mir-200c are found in the
subnetwork, with hsa-mir-22 targeting ESR1.
Table 1 Cancer associated genes in the network components and the integrated network
DAPPLE Extended Network miRNA Targets MtLasso2G Network Integrated Network
Genes 93 97 39 167
Cancer Genes[42] 20 22 6 26
Ovarian Cancer[43] 11 10 4 11
Table 2 List of cancer and ovarian cancer associated
genes in the integrated network
Genes Associated with
Cancer




























Figure 4 A subnetwork illustrating multiple data sources for
network construction. This subnetwork illustrates how the multiple
data sources are involved in the integrated network. If the network
just contained the eQTLs in green, and the miRNA-target
interactions in red, most of the connections would not exist.
Adding the protein-protein interactions of the genes, allows us to
visualize potential downstream effects.
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Conclusions
Changes in miRNA and mRNA expression are known to
be involved in both ovarian cancer development and pro-
gression. Pin-pointing the exact changes and the relation-
ships that occur between them could lead to advances in
how ovarian cancer is treated and diagnosed. Creating an
integrated network involving eQTLs, miRNA targets,
protein-protein interactions and correlation graphs is one
way to explore these relationships. Integrating multiple
data sources allows us to create a wider and more holistic
view of the interactions in ovarian cancer. This can lead
us to understanding more about the underlying mechan-
isms that affect progression in ovarian cancer.
Therefore, in this paper we developed a new method of
constructing an integrated network by combining the
strength of eQTL study and network analysis. As a
demonstration, we applied our method to TCGA ovarian
cancer data and constructed an integrated network of
miRNA and gene interactions in ovarian cancer. Utilizing
disparate data sources allowed us to find relationships that
would not have been visible otherwise. The network infor-
mation we incorporated included protein-protein interac-
tions, eQTL associations and miRNA-target interactions.
None of those interactions alone would have shown all of
the connections, but combining all these network informa-
tion together allows us to see the complex interplay
between miRNAs and genes in ovarian cancer. Our inte-
grated analysis found miRNAs and genes linked to cancer
and specifically to ovarian cancer. Utilizing integrated
approaches like this one, could lead to a more comprehen-
sive understanding of the biology that drives ovarian
cancer.
In this study we used multiple data sources including one
miRNA target database (i.e. TarBase), a protein-
protein interaction network (i.e. InWeb) and expression
data from the TCGA data portal to construct an integrated
network. Based on recent studies [15,17], it is known that
miRNAs and genetic variation have a critical impact on can-
cer progression and to an extent, cancer phenotype. Our
approach allows us to incorporate various data sources
into an integrated network. The generated network con-
tained miRNA to target gene relationships, eQTL associa-
tions, protein-protein interactions, the correlations or co-
expressions among microRNAs and genes respectively.
In the future, we will extend our approach by incorpor-
ating multiple databases of a particular network type, such
as the STRING database [62] for protein-protein interac-
tion networks. We will also incorporate other types of net-
work information. For example, we can include regulatory
and signaling pathways accumulated in existing pathway
databases. Using various data sources, we can exploit the
relationships between different molecular components to
Table 3 Number and names of miRNAs that are disease associated, cancer associated and ovarian cancer associated
respectively
miRNAs Disease associated miRNA Cancer associated miRNA Ovarian Cancer associated miRNA
Number 22 19 14 12
Names hsa-let-7d hsa-mir-1180 hsa-mir-149 hsa-mir-149
hsa-mir-1180 hsa-mir-1228 hsa-mir-181c hsa-mir-181c
hsa-mir-1228 hsa-mir-1301 hsa-mir-192 hsa-mir-192
hsa-mir-1301 hsa-mir-149 hsa-mir-200c hsa-mir-200c
hsa-mir-1306 hsa-mir-181c hsa-mir-22 hsa-mir-22
hsa-mir-149 hsa-mir-192 hsa-mir-223 hsa-mir-223
hsa-mir-181c hsa-mir-200c hsa-mir-361 hsa-mir-375
hsa-mir-192 hsa-mir-22 hsa-mir-375 hsa-mir-379
hsa-mir-1976 hsa-mir-223 hsa-mir-379 hsa-mir-503
hsa-mir-200c hsa-mir-361 hsa-mir-409 hsa-mir-584
hsa-mir-22 hsa-mir-375 hsa-mir-503 hsa-mir-625
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help understand how ovarian cancer progresses. Although
ovarian cancer is a very complex disease, our approach is a
leading step for future investigative methods.
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